

Cover Story
By Alexandria Carolan and Paul Goldberg
Budget increases in 2020 enabled NCI to boost funding for research project grants, pushing the payline up by two percentage points from last year's level.
By Matthew Bin Han Ong
In Brief


Clinical Roundup


Drugs & Targets


NCI Trials


NCI Trials for September 2020
The National Cancer Institute approved the following clinical research studies last month.
Trending Stories
- Spending bill passed by the House gives NIH $415M raise, NCI gets $128M
Legislation caps proportion of NIH grants to receive multiyear funding; indirect costs remain untouched - Blood Cancer United: A new name at the right moment
- An oncologist navigates terminal sarcoma, insurmountable debt, and “a legacy of grief”
How colleagues and Fargo, ND, neighbors came together to help the Erickson-Abou Zahrs - Premarin’s 84-year hold on the market ends as FDA approves a generic version
Trade secret protections helped the hormone drug resist generic entry and outlast safety controversies—including link to cancer - In The Headlines: Is early detection always good? Inside NCI’s MCD feasibility trial.
- Opening doors to immunotherapy in prostate cancer: A roadmap from clinic to community













